PAS-004(PAS-004) - 药物靶点：MEK1 x MEK2_在研适应症：神经纤维瘤病1型，丛状神经纤维瘤，晚期恶性实体瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

CIP-1374、PAS 004

靶点

MEK1 x MEK2

作用方式

抑制剂

作用机制

MEK1抑制剂(双特异性丝裂原活化蛋白激酶激酶1抑制剂)、MEK2抑制剂(双特异性丝裂原活化蛋白激酶激酶2抑制剂)

治疗领域

肿瘤神经系统疾病遗传病与畸形+ [7]

在研适应症

神经纤维瘤病1型丛状神经纤维瘤晚期恶性实体瘤+ [4]

非在研适应症-

原研机构

The Trustees of Columbia University in The City of New York

在研机构

Pasithea Therapeutics Corp.

非在研机构-

权益机构

无锡合全药业有限公司

Pasithea Therapeutics Corp.

AlloMek Therapeutics LLC

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看时间轴

关联

3

项与 PAS-004 相关的临床试验

NCT06961565

/ Recruiting临床1期

A Phase 1/1b Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PAS-004, a MAPK/ERK Kinase 1/2 (MEK 1/2) Inhibitor, in Adult Participants With Neurofibromatosis Type 1 (NF1) With Symptomatic and Inoperable, Incompletely Resected, or Recurrent Plexiform Neurofibromas

The main purpose of this clinical trial is to test PAS-004 in people with at least one symptomatic plexiform neurofibroma due to Neurofibromatosis Type 1 (NF1). The main questions it aims to answer are:
* How well participants are able tolerate different doses of PAS-004, and
* What side effects PAS-004 might have.
This study will have two parts, Part A and Part B. The main goal of Part A of this study is to learn more about how participants tolerate different doses of PAS-004, and what side effects PAS-004 might have. What we learn from Part A of the study will help decide what doses of the study drug (PAS-004) should be used in Part B of the study, and if it is safe.
In Part B, two different doses from Part A will be tested. The main goal of this part of the study is to keep studying any side effects of PAS-004 at those two dose levels, and to learn more about if the doses picked for this part of the study might have an effect on plexiform neurofibromas.
Participants in Part A of the study who were taking doses selected for Part B may be able to continue on to Part B and keep taking the same dose of PAS-004 for 6 more months.
Study participants in both parts will have regular visits to the study doctor and be asked to have tests and exams done to check on their health and safety, including blood draws and MRIs. Everyone participating in the study will take PAS-004 by mouth once a day during the study, in 28-day cycles. Participants will be asked to keep a diary to record their daily dose of study drug.
Participants will continue on daily PAS-004 for up to 6 months, or until:
* They decide to withdraw from the study, or
* They experience unacceptable side effects, or
* Their disease progresses, or another illness interferes with taking the study drug, or
* The sponsor selects a dose level to study further in the next part of the study, or
* The sponsor stops the study.

开始日期2025-05-30

申办/合作机构

Pasithea Therapeutics Corp.

[+1]

CTIS2024-510900-34-00

/ Recruiting临床1期

A Phase 1 Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAS-004, a MEK (1/2) Inhibitor, in Patients with MAPK Pathway-driven Advanced Solid Tumors with a Documented RAS, NF1, or RAF Mutation or Patients who have Failed BRAF/MEK Inhibition

开始日期2024-11-22

申办/合作机构

Pasithea Therapeutics Corp.

NCT06299839

/ Recruiting临床1期

A Phase 1 Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAS-004, a MEK (1/2) Inhibitor, in Patients With MAPK Pathway-driven Advanced Solid Tumors With a Documented RAS, NF1, or RAF Mutation or Patients Who Have Failed BRAF/MEK Inhibition

The main purpose of this clinical trial is to test PAS-004 in people with advanced solid tumors with rat sarcoma virus (RAS), neurofibromatosis type I (NF1), or rapidly accelerated fibrosarcoma (RAF) mutations. The main questions it aims to answer are:
* How well participants are able tolerate different doses of PAS-004, and
* What side effects PAS-004 might have.
Study participants will have regular visits to the study doctor and be asked to have tests and exams done to check on their health and safety. Everyone participating in the study will take PAS-004 by mouth as a single dose, followed by one week observation, then once a day during the study, in 28-day cycles. Participants will continue on daily PAS-004 for up to 2 years, or until:
* They decide to withdraw from the study, or
* They experience unacceptable side effects, or
* Their disease progresses, or another illness interferes with taking the study drug, or
* The sponsors stops the study.

开始日期2024-02-29

申办/合作机构

Pasithea Therapeutics Corp.

100 项与 PAS-004 相关的临床结果

登录后查看更多信息

100 项与 PAS-004 相关的转化医学

登录后查看更多信息

100 项与 PAS-004 相关的专利（医药）

登录后查看更多信息

1

项与 PAS-004 相关的文献（医药）

2026-02-01·JOURNAL OF ETHNOPHARMACOLOGY

Inhibition of melanogenesis by ginseng phenolic Acids: Suppressed melanosome maturation, melanocyte transport, and keratinocyte uptake

Article

作者: Xu, Xiaohao ; Sun, Liwei ; Liu, Jianzeng ; Guo, Yonggang ; Sun, Guang ; Jiang, Rui ; Wang, Jing ; Li, Zhenzhuo ; Zhai, Lu

ETHNOPHARMACOLOGICAL RELEVANCE:

Ginseng phenolic acid extract (GPAE), composed of five phenolic acids (protocatechuic acid, PA; vanillic acid,VA; p-coumaric acid, p-CA; salicylic acid, SA; and caffeic acid, CA), suppresses UVB-induced melanin overproduction. However, UV-induced skin darkening involves broader melanin metabolism, including melanosome maturation, transport to dendrites, and transfer to keratinocytes. GPAE's overall effects on these processes and its key active components remain unclear.

AIM OF THE STUDY:

To identify the effects and mechanisms of GPAE and its phenolic acids on melanosome transfer, providing a mechanistic explanation for the antipigmentation properties of ginseng root.

METHODS:

The effects of GPAE or its phenolic acids were tested in UVB-irradiated mice and B16F10 and HaCaT cells. Skin and cell samples were analyzed using various staining, microscopy, and molecular techniques to assess structure, melanin deposition, and protein expression.

RESULTS:

GPAE suppressed UVB-induced skin hyperpigmentation in mice by lightning skin, thinning the epidermis, and decreasing basal-layer pigmentation. GPAE downregulated melanosome transport proteins Myosin Va (Myo Va), melanophilin (Mlph), Rab27a, and the melanophage-associated receptor PAR2. In UVB-exposed B16F10 cells, GPAE reduced melanin content and accumulation, shortened dendrite length, inhibited dendritic proliferation, and disrupted melanosome maturation by decreasing stage III-IV melanosomes and increasing stage I-II populations. A composite mixture, PAs(4) (PA/VA/p-CA/SA), formulated at GPAE-equivalent ratios, similarly downregulated Mlph, Rab27a, and Myo Va expression. Another blend, PAs(3) (PA/VA/SA), replicated GPAE's inhibition of HaCaT cell-mediated phagocytosis. Both GPAE and PAs(3) inhibited UVB-induced PAR2 upregulation, intracellular Ca²⁺ levels, and PI3K, AKT, JNK, ERK, and p38 phospherylation.

CONCLUSION:

GPAE alleviates UVB-induced hyperpigmentation by inhibiting melanosome maturation and dendritic transport in melanocytes and reducing keratinocyte melanosome uptake via the PAR2-Ca²⁺-PI3K-AKT-MAPK pathway. Key active phenolic acids were identified, providing mechanistic insight into ginseng's antimelanogenic effects.

47

项与 PAS-004 相关的新闻（医药）

2025-12-03

·GlobeNewswire-Health Care

Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

Extends cash runway through at least the first half of 2028 Led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners and Squadron Capital Management Dec. 02, 2025 -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (Nasdaq: KTTA; KTTAW), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), today announced the closing of its previously announced public offering of 80,000,000 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.75 per share of common stock (or per pre-funded warrant in lieu thereof). The public offering was led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners and Squadron Capital Management. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering were approximately $60 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for general corporate purposes. The Company expects its cash position to extend its cash runway through at least the first half of 2028. Such corporate purposes include, without limitation, ongoing research and pre-clinical studies, clinical trials, the development of new biological and pharmaceutical technologies, investing in or acquiring companies that are synergistic with or complementary to the Company’s technologies, licensing activities related to its current and future product candidates, and to the development of emerging technologies, investing in or acquiring companies that are developing emerging technologies, licensing activities, or the acquisition of other businesses and working capital. The securities described above were offered pursuant to a registration statement on Form S-1 (File No. 333-291611) originally filed with the Securities and Exchange Commission (“SEC”) on November 18, 2025, as amended on November 26, 2025, and declared effective on November 28, 2025. The offering was made only by means of a prospectus, which is part of the effective registration statement. A final prospectus relating to the offering has been filed with the SEC. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Pasithea is a clinical-stage biotechnology company primarily focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The Company is currently testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients (NCT06299839), and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NCT06961565). The content above comes from the network. if any infringement, please contact us to modify.

融资

2025-12-02

·ir.pasithea.com

Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

Extends cash runway through at least the first half of 2028 Led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners and Squadron Capital Management MIAMI, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (Nasdaq: KTTA; KTTAW), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), today announced the closing of its previously announced public offering of 80,000,000 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.75 per share of common stock (or per pre-funded warrant in lieu thereof). The public offering was led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners and Squadron Capital Management. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering were approximately $60 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for general corporate purposes. The Company expects its cash position to extend its cash runway through at least the first half of 2028. Such corporate purposes include, without limitation, ongoing research and pre-clinical studies, clinical trials, the development of new biological and pharmaceutical technologies, investing in or acquiring companies that are synergistic with or complementary to the Company’s technologies, licensing activities related to its current and future product candidates, and to the development of emerging technologies, investing in or acquiring companies that are developing emerging technologies, licensing activities, or the acquisition of other businesses and working capital. The securities described above were offered pursuant to a registration statement on Form S-1 (File No. 333-291611) originally filed with the Securities and Exchange Commission (“SEC”) on November 18, 2025, as amended on November 26, 2025, and declared effective on November 28, 2025. The offering was made only by means of a prospectus, which is part of the effective registration statement. A final prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus may be obtained for free on the SEC’s website located at http://www.sec.gov and may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. About Pasithea Therapeutics Corp. Pasithea is a clinical-stage biotechnology company primarily focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The Company is currently testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients (NCT06299839), and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NCT06961565). Forward Looking Statements This press release contains statements that constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the use of proceeds from the public offering and the Company’s cash runway, the Company’s ongoing Phase 1 clinical trial of PAS-004 in advanced cancer patients, the Company’s ongoing Phase 1/1b clinical trial of PAS-004 in adult NF1 patients, and the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD) and preliminary efficacy of PAS-004, as well as all other statements, other than statements of historical fact, regarding the Company’s current views and assumptions with respect to future events regarding its business, as well as other statements with respect to the Company’s plans, assumptions, expectations, beliefs and objectives, the success of the Company’s current and future business strategies, product development, pre-clinical studies, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth and financing opportunities and other statements that are predictive in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including risks that future clinical trial results may not match results observed to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory approval, as well as other factors set forth in the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings made with the SEC. Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law. Pasithea Therapeutics Contact Patrick Gaynes Corporate Communications pgaynes@pasithea.com Released December 2, 2025

临床1期

2025-12-01

·药明康德

创新“p53合成激活”抗癌分子胶进入临床；大环MEK抑制剂获积极临床结果…… | 一周盘点

本期看点： 1. Pin Therapeutics公司基于其创新“p53合成激活（synthetic activation of p53）”机制开发的口服CK1α选择性降解剂PIN-5018已在1期临床试验中完成首例患者给药。 2. 大环MEK抑制剂PAS-004用于治疗神经纤维瘤病，在一项早期临床研究中取得了积极的药代动力学（PK）数据。 PIN-5018：1期临床试验完成首例患者给药 Pin Therapeutics公司宣布，其基于公司提出的创新机制“p53合成激活”开发的口服CK1α选择性降解剂PIN-5018，已在1期临床试验中完成首例患者给药。该患者罹患腺样囊性癌（ACC），这是一种罕见且治疗选择有限的恶性肿瘤。在两个患者来源异种移植（PDX）ACC模型中，PIN-5018展现出显著的抗肿瘤活性：其中一模型实现完全缓解（CR），另一模型出现明显肿瘤缩小，为推进临床研究提供了有力支持。除ACC外，公司还计划将PIN-5018拓展至转移性去势抵抗性前列腺癌（mCRPC）、结直肠癌及其他罕见肿瘤领域。 PAS-004：公布1/1b期临床试验数据 Pasithea Therapeutics公司公布了其大环MEK抑制剂PAS-004用于治疗成人神经纤维瘤病1型相关丛状神经纤维瘤（NF1-PN）的积极1/1b期临床试验数据。与目前FDA批准的MEK抑制剂不同，PAS-004是大环化合物，环化可增强药物与靶受体的结合，被认为有望改善药代动力学和安全性。此次公布的结果显示，PAS-004片剂的PK暴露量随剂量增加呈比例上升，半衰期约57小时。片剂更优的PK特性使得更低剂量即可达到与胶囊相同的暴露水平，同时具备更高的可预测性和更低的个体间差异。在稳态下，片剂的Cmax/Cmin比值＜2。 VT-5006：启动1期临床试验 Vertero Therapeutics公司宣布启动其潜在“first-in-class”、用于治疗帕金森病的肠道选择性小分子药物VT-5006的1期研究。该药物通过作用于胃肠道壁中存在的微生物淀粉样蛋白CsgA开发，CsgA能驱动α-突触核蛋白（⍺Syn）的聚集和炎症反应，炎症传播至大脑将引发帕金森病进展。VT-5006旨在通过靶向CsgA减少⍺Syn聚集负荷并抑制炎症，从而可能缓解症状并减缓疾病进程，帮助患者维持功能状态。此次开展的试验基于前期令人鼓舞的临床前研究结果，这些研究表明VT-5006可以减少脑部病理变化和炎症，改善运动功能并延缓疾病进展，同时表现出良好的安全性特征。参考资料： [1] Parabilis Medicines Highlights Promising Preliminary Clinical Results in Patients with Adamantinomatous Craniopharyngioma from Ongoing FOG-001 Clinical Trial at SNO 2025. Retrieved November 28, 2025, from https://www.businesswire.com/news/home/20251121107097/en/Parabilis-Medicines-Highlights-Promising-Preliminary-Clinical-Results-in-Patients-with-Adamantinomatous-Craniopharyngioma-from-Ongoing-FOG-001-Clinical-Trial-at-SNO-2025 [2] Kelonia Therapeutics Announces Late-Breaking Oral Presentation of First-in-Human Data from in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting. Retrieved November 28, 2025, from https://keloniatx.com/kelonia-therapeutics-announces-late-breaking-oral-presentation-of-first-in-human-data-from-in-vivo-bcma-car-t-therapy-at-the-american-society-of-hematology-ash-2025-annual-meeting/ [3] Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer. Retrieved November 28, 2025, from https://www.prnewswire.com/news-releases/data-from-genprexs-acclaim-1-phase-1-gene-therapy-clinical-trial-published-in-clinical-lung-cancer-302623852.html [4] Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients. Retrieved November 28, 2025, from https://www.globenewswire.com/news-release/2025/11/21/3192937/0/en/Pasithea-Therapeutics-Announces-Positive-PAS-004-Tablet-Pharmacokinetic-PK-Data-in-Ongoing-Phase-1-1b-Trial-in-Adult-NF1-Patients.html [5] Vertero Initiates Phase 1 Study of VT-5006, A Selective Small Molecule Therapy for Parkinson’s Disease. Retrieved November 28, 2025, from https://www.globenewswire.com/news-release/2025/11/24/3193400/0/en/Vertero-Initiates-Phase-1-Study-of-VT-5006-A-Selective-Small-Molecule-Therapy-for-Parkinson-s-Disease.html [6] Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence. Retrieved November 28, 2025, from https://ir.harmonybiosciences.com/news-releases/news-release-details/harmony-biosciences-announces-initiation-first-human-study [7] Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrader PIN-5018 in Phase 1 Trial. Retrieved November 28, 2025, from https://www.prnewswire.com/news-releases/pin-therapeutics-initiates-first-patient-dosing-of-ck1-degrader-pin-5018-in-phase-1-trial-302624301.html 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床1期临床结果临床2期

100 项与 PAS-004 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
神经纤维瘤病1型	临床1期	美国	Pasithea Therapeutics Corp.	2025-05-30
神经纤维瘤病1型	临床1期	澳大利亚	Pasithea Therapeutics Corp.	2025-05-30
神经纤维瘤病1型	临床1期	韩国	Pasithea Therapeutics Corp.	2025-05-30
丛状神经纤维瘤	临床1期	美国	Pasithea Therapeutics Corp.	2025-05-30
丛状神经纤维瘤	临床1期	澳大利亚	Pasithea Therapeutics Corp.	2025-05-30
丛状神经纤维瘤	临床1期	韩国	Pasithea Therapeutics Corp.	2025-05-30
晚期恶性实体瘤	临床1期	美国	Pasithea Therapeutics Corp.	2024-02-29
晚期恶性实体瘤	临床1期	保加利亚	Pasithea Therapeutics Corp.	2024-02-29
晚期恶性实体瘤	临床1期	罗马尼亚	Pasithea Therapeutics Corp.	2024-02-29
肌萎缩侧索硬化	临床前	美国	Pasithea Therapeutics Corp.	2025-11-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06299839 (Company_Website) 人工标引	临床1期	晚期癌症	27	PAS-004	製窪鹹餘壓範構築築築(淵願夢餘鬱繭築範鬱簾) = 艱蓋憲膚鬱醖壓顧窪蓋艱淵獵鬱鏇膚鏇夢襯獵 (觸構窪獵夢顧壓衊醖築 ) 更多	积极	2025-11-20
NCT06299839 (Phase I dose-escalation study of PAS-004, ASCO2025)	临床1期	MAPK突变实体瘤 RAS \| NF1 \| RAF mutation ... 更多	9	PAS-004 2mg	獵簾鑰窪艱繭鹽鹽獵顧(鹹襯願醖膚鑰顧繭網繭) = 鏇築鹽網夢願艱構壓顧鏇艱窪製窪構顧餘願艱 (選壓膚蓋網願顧遞夢簾 ) 更多	积极	2025-05-30
NCT06299839 (Company_Website) 人工标引	临床1期	晚期恶性实体瘤	-	PAS-004 (8mg and 15mg capsules)	構遞鏇衊艱積艱膚鏇淵(網選壓廠鏇餘製獵廠艱) = 願遞蓋醖夢齋願獵觸憲鏇鹽衊鹽積積壓糧憲齋 (夢遞壓廠製遞鏇鏇壓鬱 ) 更多	积极	2025-05-06
NCT06299839 (Company_Website) 人工标引	临床1期	晚期癌症	19	PAS-004 capsule (15 patients) or tablet (four patients)	壓觸遞窪鹹範廠顧選鬱(夢膚齋壓糧膚範獵觸願) = None 範窪鹹膚夢鬱壓艱膚獵 (壓蓋憲製餘糧淵淵觸構 )	积极	2025-04-10
NCT06299839 (Company_Website) 人工标引	临床1期	晚期癌症	6	PAS-004	憲壓壓鏇選齋齋遞範遞(鏇襯繭廠艱艱構鬱鑰選) = none 壓構夢壓網憲夢鹽襯顧 (鹹襯襯壓鬱夢範觸膚鏇 ) 更多	积极	2024-09-26